Compare AMBO & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | XBIO |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.8M |
| IPO Year | 2010 | 2011 |
| Metric | AMBO | XBIO |
|---|---|---|
| Price | $1.83 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 99.8K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 337.04 | 38.52 |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $9,469,000.00 | $2,976,411.00 |
| Revenue This Year | N/A | $2.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $379.59 | ★ N/A |
| Revenue Growth | 0.82 | ★ 19.04 |
| 52 Week Low | $1.47 | $1.90 |
| 52 Week High | $6.75 | $13.93 |
| Indicator | AMBO | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 34.54 |
| Support Level | $1.69 | $2.14 |
| Resistance Level | $2.31 | $2.62 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 0.00 | 2.65 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.